Cargando...
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs()
Histone deacetylases (HDACs) are validated drug targets for cancer treatment. Increased HDAC isozyme selectivity and novel strategies to inhibit HDAC activity could lead to safer and more effective drug candidates. Nonetheless, it is quite challenging to develop isozyme-specific HDACi due to the hig...
Guardado en:
| Publicado en: | Chem Commun (Camb) |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7654701/ https://ncbi.nlm.nih.gov/pubmed/32840532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/d0cc03243c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|